Co-Diagnostics Expands its Diagnostic Product Reach in Latin America with New Mexico Agreement

Co-Diagnostics Expands in Latin America

Co-Diagnostics, Inc., known for its innovative molecular diagnostics, is poised to enhance its commercial strategies in Latin America following a new distribution agreement in Mexico. This significant deal bolsters the company’s existing relationship with its long-term partner in the region, which previously played a crucial role during the COVID-19 pandemic.

The agreement focuses on the Co-Dx™ PCR Pro®, a point-of-care platform, which includes the PCR Pro® instrument and essential test kits required for advanced molecular diagnostics. With the announcement made on June 11, 2026, Co-Diagnostics aims to broaden its diagnostic offerings as it prepares for the upcoming product launch. However, this launch is contingent upon receiving the necessary regulatory approvals.

Dwight Egan, the CEO of Co-Diagnostics, expressed enthusiasm about continuing their collaboration, highlighting the distributor’s past success in introducing molecular diagnostic products during critical health challenges. He noted that the agreement not only reinforces their existing ties but also positions Co-Diagnostics well for further introducing a variety of point-of-care molecular diagnostics in Mexico, the second most populous market in Latin America.

As the market evolves, Co-Diagnostics has expanded its test portfolio from solely COVID-19 testing to include various infectious diseases like tuberculosis, HPV, and mpox. Their ongoing initiative includes developing assays for diseases such as H5N1 and a newly announced Ebola test, showcasing the company’s commitment to responding quickly to changing health needs across global diagnostics.

Since the onset of their partnership in 2020, Co-Diagnostics has achieved revenues exceeding $18 million through the sale of Logix Smart® PCR tests and laboratory equipment. Their COVID-19 testing accounted for over half of all tests administered in Mexico in 2021, reflecting the effectiveness of their distribution network.

This exclusive agreement for the Co-Dx PCR platform in Mexico extends for an additional five years, allowing for a sustained commitment to advancing molecular diagnostics in the region. The current Co-Dx PCR platform comprises several components, including the PCR Home®, PCR Pro®, and related mobile applications, all of which await regulatory clearances before market availability.

As the diagnostic landscape shifts and expands post-pandemic, the agility and high-quality technology provided by Co-Diagnostics play a pivotal role. The ability to adapt their offerings will help meet future demands while ensuring that rapid response capabilities remain an essential part of their business model.

Overall, this endeavor by Co-Diagnostics not only marks a crucial step in the growth of their operational reach within Latin America but also signifies a broader push toward enhancing healthcare capabilities and accessibility in the region. The integration of advanced molecular diagnostics promises to transform testing and diagnosis methods, ultimately benefiting public health outcomes.

Conclusion

In conclusion, Co-Diagnostics is making significant strides in technical advancement and market penetration within Latin America through strategic distribution partnerships. With the Co-Dx™ PCR platform on the horizon, the company looks forward to solidifying its presence and expanding its product offerings across Mexico and potentially beyond. Both the company and its distributor will likely benefit as they work together to enhance the availability of critical diagnostic tools in a rapidly changing healthcare environment.